Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

4
72
2

Year Published

2017
2017
2022
2022

Publication Types

Select...
7
2

Relationship

3
6

Authors

Journals

citations
Cited by 88 publications
(78 citation statements)
references
References 5 publications
4
72
2
Order By: Relevance
“…A small number of brain‐biopsied cases with MOG‐IgG‐positive tumefactive brain lesions have been reported, and the pathological findings are characterized by so‐called MS type II pathology (active inflammatory demyelination with deposition of immunoglobulins and complements) . Our studies on cell damage markers in the CSF during acute exacerbations showed that regardless of the clinical phenotypes, the CSF MBP level was high, whereas the CSF‐glial fibrillary acidic protein level was not elevated at all, clearly showing that MOG‐IgG‐positive disease is an inflammatory demyelinating disease, even if the clinical phenotype is NMO …”
Section: Pathology and Pathomechanismsmentioning
confidence: 65%
See 1 more Smart Citation
“…A small number of brain‐biopsied cases with MOG‐IgG‐positive tumefactive brain lesions have been reported, and the pathological findings are characterized by so‐called MS type II pathology (active inflammatory demyelination with deposition of immunoglobulins and complements) . Our studies on cell damage markers in the CSF during acute exacerbations showed that regardless of the clinical phenotypes, the CSF MBP level was high, whereas the CSF‐glial fibrillary acidic protein level was not elevated at all, clearly showing that MOG‐IgG‐positive disease is an inflammatory demyelinating disease, even if the clinical phenotype is NMO …”
Section: Pathology and Pathomechanismsmentioning
confidence: 65%
“…41,42 Our studies on cell damage markers in the CSF during acute exacerbations showed that regardless of the clinical phenotypes, the CSF MBP level was high, whereas the CSF-glial fibrillary acidic protein level was not elevated at all, clearly showing that MOG-IgG-positive disease is an inflammatory demyelinating disease, even if the clinical phenotype is NMO. 43,44 Data on immunological abnormalities in MOG-IgG-positive disease are insufficient, but T helper cell 17, B cells and neutrophil-related cytokines seem to be upregulated in the CSF during the acute phase of the disease. 45 Although pathogenicity of MOG-IgG has not been clarified, there have been some reports supporting it.…”
Section: Pathology and Pathomechanismsmentioning
confidence: 99%
“…35,36 Moreover, we recently reported high CSF-MBP levels without elevated CSF glial fibrillary acidic protein levels, an astrocytic damage marker, in MOG antibody–positive patients. 37 These findings suggest that MOG antibody may directly contribute to inflammatory demyelination in anti–myelin antibody–associated CNS diseases. However, in 3 of our MOG antibody–positive cases whose CSF-MBP levels were measured during the acute phase, there was no elevation in CSF-MBP despite the extensive cortical involvement and CSF pleocytosis.…”
Section: Discussionmentioning
confidence: 88%
“…In addition, only patients who were seropositive were enrolled because we did not perform the test of myelin oligodendrocyte glycoprotein (MOG) autoimmunity, a distinct spectrum differentiated from seronegative NMOSD, which can limit the generalization of our data to seronegative NMOSD. [41, 42] Finally, other factors including socioeconomic variables that can affect fatigue or QOL,[43] were not investigated in this study, although we completed the comprehensive investigations of possible contributing factors of QOL (fatigue, sleep quality, depression, and pain), in remission.…”
Section: Discussionmentioning
confidence: 99%